A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients

Inclusion Criteria: 1. Non-keratinizing nasopharyngeal carcinoma diagnosed by pathology; 2. According to the UICC/AJCC eighth edition staging criteria, clinical staging was T1-4N2 -3M0 (stage N2-3 nasopharyngeal carcinoma); 3. Patients who have not received disease-related anti-tumor system therapy; 4. Age 18\~70 years; 5. Perfect liver and kidney function: total bilirubin ≤1.5 times the upper limit of normal value (ULN); AST and ALT≤2.5 ULN; Alkaline phosphatase ≤2.5 ULN; Creatinine clearance rate ≥80 mL/min; 6. Complete blood system function: neutrophil count (ANC) ≥2×109/L, platelet count ≥100×109/L and hemoglobin ≥9 g/dL; 7. Cartesian score ≥70; or ECOG PS 0 or 1 8. Prior to enrollment, the patients must undergo nasopharynx + neck MRI, chest + upper abdomen CT, ECT and other examinations of the whole body bone. 9. Sign the informed consent. Exclusion Criteria: 1. Patients with distant metastases were identified at the time of diagnosis; 2. Patients with severe medical complications, severe organ (heart, lung) dysfunction, or neuropsychiatric disorders at the time of diagnosis; 3. Previous cases of other malignancies;Complicated with other malignant tumors;Except for cured basal cell carcinoma of the skin or squamous cell carcinoma of the skin or carcinoma in situ of any other site; 4. Use any other investigational drug or participate in another clinical trial with therapeutic intent within 3 months prior to enrollment; 5. A woman who is pregnant or lactating; 6. Known active HIV or HBV, HCV infection; 7. Known to be allergic to drugs that may be used; 8. The researchers did not consider participants to be eligible for this study.